Home>Topics>Stocks>Holly Energy Partners

Holly Energy Partners HEP

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Vertex’s 3Q Results as Expected but Kalydeco Guidance Lowered; Stock Remains Modestly Undervalued

      Commentary

      Wed, 29 Oct 2014

      quarter was $179.0 million, down from $221.7 million, driven by the Incivek sales drop due to superior new products in the Hep C market. Kalydeco revenues grew 25% year over year to $126.8 million, due to label expansion in the U.S. beyond the

    2. Gilead Sciences: Pricing, Politics And Profits

      Headlines

      Tue, 21 Oct 2014

      Gilead Sciences (NASDAQ: GILD ), and a commenter requested an article about the politics surrounding Gilead's pricing of its Hep C drugs Sovaldi, and more recently, Harvoni. So, I began going through various articles, news reports and company statements

    3. FDA clears Gilead hep C combo pill

      Headlines

      Fri, 10 Oct 2014

      The FDA approves Gilead Sciences' ( GILD -0.3% ) Harvoni for the treatment of chronic hepatitis C genotype 1 infection. Harvoni is a combination of ledipasvir and sofosbuvir . It is the first approved regimen that does not require administration with interferon or ribavirin. This is the third HCV

    4. Arrowhead plunges on hep B drug data

      Headlines

      Wed, 8 Oct 2014

      Micro cap Arrowhead Research ( ARWR -51% ) plunges on massive turnover of 35M shares in response to its disclosure of Phase 2 trial results for its experimental hepatitis B therapy, ARC-520 . In data released in the "Late-breaking abstracts" section of the American Association For The Study Of ...

    5. Called Strike 3 For Bristol-Myers Squibb: What This Says For Gilead And Its Competitors In The Hep C Market

      Headlines

      Wed, 8 Oct 2014

      By Pharma Doc : Background: The hepatitis C landscape is an extremely competitive area for pharmaceuticals and biotechs. Years ago, the standard of care for HCV genotype 1 patients was Pegasys and Ribavirin for 48 weeks of treatment. Side effects were very bad (nausea and flu-like symptoms), and ...

    6. PDUFA date approaches for Gilead hep C combo

      Headlines

      Tue, 7 Oct 2014

      The FDA's PDUFA date for its review of Gilead Sciences' ( GILD -0.1% ) NDA for the combination of ledipasvir and sofosbuvir for the treatment of hepatitis C genotype 1 infection in adults is October 10. The European Medicines Agency's CHMP adopted a positive opinion recommending approval for the ...

    7. UPDATE 2-Bristol-Myers pulls U.S. marketing application for hep C treatment

      Headlines

      Tue, 7 Oct 2014

      (Adds comment from Bristol-Myers and analyst, adds background, updates shares)

    8. Bristol-Myers pulls hep C NDA

      Headlines

      Tue, 7 Oct 2014

      BMY ) decides not to pursue U.S. regulatory approval of the dual regimen of daclatasvir and asunaprevir for the treatment of hep C 1b. As a result, it withdraws its NDA for its NS3/4A protease inhibitor , asunaprevir. The company will continue to pursue

    9. The Question Isn't If Gilead's Hep C Combo Will Be Approved In The US By Next Friday; The Question Is The Price Of The Regimen

      Headlines

      Fri, 3 Oct 2014

      By Pharma Doc : Background: Gilead's (NASDAQ: GILD ) Sofosbuvir (Sovaldi) was approved by the FDA in late 2013 and has shattered the record for the best drug launch in history. In its first two quarters, Sovaldi has sold $5.7B and is anticipated to sell $10-$12B in 2014. Gilead's current regimen ...

    10. France to tax hep C drug makers in order to curb costs

      Headlines

      Tue, 30 Sep 2014

      selected hepatitis C drug makers if the cost to the government exceeds a certain amount each year. If social security spending on hep C drugs exceeds €450M in 2014, the drug makers will be taxed based on the revenue that exceeds the cap. The cap in 2015

    « Prev12345Next »
    Content Partners